NASDAQ:AQST - Aquestive Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.89 -0.69 (-8.04 %)
(As of 12/12/2018 04:00 PM ET)
Previous Close$8.58
Today's Range$7.79 - $8.58
52-Week Range$7.47 - $20.70
Volume102,400 shs
Average Volume132,854 shs
Market Capitalization$205.77 million
P/E RatioN/A
Dividend YieldN/A
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:AQST
Previous Symbol


Debt-to-Equity Ratio1.88
Current Ratio3.63
Quick Ratio3.42


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares24,940,000
Market Cap$205.77 million
OptionableNot Optionable

Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics Inc (NASDAQ:AQST) announced its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.15. The business earned $13.27 million during the quarter, compared to analysts' expectations of $14.75 million. View Aquestive Therapeutics' Earnings History.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Aquestive Therapeutics.

What price target have analysts set for AQST?

4 equities research analysts have issued 1 year price targets for Aquestive Therapeutics' shares. Their predictions range from $24.00 to $30.00. On average, they expect Aquestive Therapeutics' stock price to reach $27.6667 in the next year. This suggests a possible upside of 250.7% from the stock's current price. View Analyst Price Targets for Aquestive Therapeutics.

What is the consensus analysts' recommendation for Aquestive Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquestive Therapeutics.

Has Aquestive Therapeutics been receiving favorable news coverage?

News articles about AQST stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aquestive Therapeutics earned a daily sentiment score of 3.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Aquestive Therapeutics' key competitors?

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the folowing people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 60)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 53)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer and Director (Age 59)
  • Mr. Daniel Barber, Sr. VP and Chief Strategy & Devel. Officer (Age 42)
  • Mr. Peter E. Boyd, Sr. VP of Operations & Value Delivery (Age 53)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

When does the company's lock-up period expire?

Aquestive Therapeutics' lock-up period expires on Monday, January 21st. Aquestive Therapeutics had issued 4,500,000 shares in its public offering on July 25th. The total size of the offering was $67,500,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Crestline Management LP (46.12%), Perceptive Advisors LLC (4.61%), Alliancebernstein L.P. (3.28%), BlackRock Inc. (1.89%), Vanguard Group Inc. (1.84%) and Massachusetts Financial Services Co. MA (1.21%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Institutional Ownership Trends for Aquestive Therapeutics.

Which major investors are buying Aquestive Therapeutics stock?

AQST stock was purchased by a variety of institutional investors in the last quarter, including Crestline Management LP, Perceptive Advisors LLC, Alliancebernstein L.P., BlackRock Inc., Vanguard Group Inc., Massachusetts Financial Services Co. MA, Wasatch Advisors Inc. and Baker BROS. Advisors LP. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Insider Buying and Selling for Aquestive Therapeutics.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $7.89.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $205.77 million. Aquestive Therapeutics employs 195 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]

MarketBeat Community Rating for Aquestive Therapeutics (NASDAQ AQST)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Aquestive Therapeutics and other stocks. Vote "Outperform" if you believe AQST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel